PELLUCID MARGINAL CORNEAL DEGENERATION
Clinical trials for PELLUCID MARGINAL CORNEAL DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new PELLUCID MARGINAL CORNEAL DEGENERATION trials appear
Sign up with your email to follow new studies for PELLUCID MARGINAL CORNEAL DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Shorter light therapy may be just as good for treating bulging corneas
Disease control Recruiting nowThis phase 3 trial tests whether a shorter 18-minute ultraviolet (UVA) light exposure works as well as the standard 24-minute exposure during corneal crosslinking for keratoconus and similar conditions. The treatment uses riboflavin (vitamin B2) eye drops followed by UVA light to…
Matched conditions: PELLUCID MARGINAL CORNEAL DEGENERATION
Phase: PHASE3 • Sponsor: Woolfson Eye Institute • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New light therapy aims to halt cornea disease and save sight
Disease control Recruiting nowThis study tests a device that uses riboflavin (vitamin B2) drops and UV light to stiffen the cornea, the clear front part of the eye. It is for people with keratoconus or similar conditions that cause the cornea to bulge and blur vision. The goal is to see if the treatment safel…
Matched conditions: PELLUCID MARGINAL CORNEAL DEGENERATION
Phase: PHASE2 • Sponsor: Goodman Eye Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC